Blepharitis News and Research

RSS

A common disorder of the eye, blepharitis, is a condition in which there is visible inflammation in the eyelids. Bacteria causes irritation and the eyelids become red and itchy. Though it does not cause permanent damage to vision, blepharitis causes discomfort to patients. Women in their peri- and post-menopausal stage are more prone to the dysfunction of the meibomian glands.

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

Inspire reports net loss of $17.6 million for first quarter 2011

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or per common share, as compared to a net loss of $14.8 million, or per common share, for the same period in 2010.

10 May 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Inspire Pharmaceuticals, Inc. announced today the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis.

3 Jan 2011

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.

20 Dec 2010

Santen launches DIQUAS Ophthalmic Solution in Japan

Inspire Pharmaceuticals, Inc. announced that DIQUAS Ophthalmic Solution 3% (diquafosol tetrasodium) received pricing approval and was launched for sale today in Japan by its partner, Santen Pharmaceutical Co., Ltd. Inspire will receive a related milestone payment of $1.25 million in the fourth quarter of 2010 and is also entitled to receive payments based upon a tiered royalty rate on net sales of DIQUAS in Japan, with a minimum rate in the high single digits and a maximum rate in the low double digits.

From Santen Pharmaceutical Co., Ltd. 13 Dec 2010

Inspire third quarter net loss decreases to $7.6 million

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2010, reporting a net loss of $7.6 million or ($0.09) per share, an improvement from the third quarter of 2009 during which the Company incurred a net loss of $8.5 million or ($0.12) per share.

4 Nov 2010

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the 24th Annual North American Cystic Fibrosis Conference (NACFC) October 21-23, 2010 in Baltimore, Maryland.

22 Oct 2010

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.

17 Sep 2010

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.

25 Aug 2010

Inspire second-quarter total revenue increases 18% to $27.3 million

Inspire Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2010, reporting a net loss of $8.8 million or ($0.11) per share, an improvement from the second quarter of 2009 during which the Company incurred a net loss of $9.5 million or ($0.17) per share.

5 Aug 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2010, reporting a net loss of $14.8 million or ($0.18) per share.

3 May 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals, Inc. announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.

15 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

Patient enrollment in three late-stage clinical trials completed

Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.